BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27259260)

  • 1. ATM protein is deficient in over 40% of lung adenocarcinomas.
    Villaruz LC; Jones H; Dacic S; Abberbock S; Kurland BF; Stabile LP; Siegfried JM; Conrads TP; Smith NR; O'Connor MJ; Pierce AJ; Bakkenist CJ
    Oncotarget; 2016 Sep; 7(36):57714-57725. PubMed ID: 27259260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
    Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
    Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MHC class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer.
    Okita R; Yukawa T; Nojima Y; Maeda A; Saisho S; Shimizu K; Nakata M
    Cancer Immunol Immunother; 2016 May; 65(5):499-509. PubMed ID: 26940474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells.
    Jiang HG; Chen P; Su JY; Wu M; Qian H; Wang Y; Li J
    J Cell Physiol; 2017 Dec; 232(12):3433-3443. PubMed ID: 28075014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma : ATM, ATR and FA in lung carcinoma.
    Beumer JH; Fu KY; Anyang BN; Siegfried JM; Bakkenist CJ
    BMC Cancer; 2015 Oct; 15():649. PubMed ID: 26438152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor-1 attenuates cisplatin-induced gammaH2AX formation and DNA double-strand breaks repair pathway in non-small cell lung cancer.
    Jeon JH; Kim SK; Kim HJ; Chang J; Ahn CM; Chang YS
    Cancer Lett; 2008 Dec; 272(2):232-41. PubMed ID: 18762365
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Schmitt A; Knittel G; Welcker D; Yang TP; George J; Nowak M; Leeser U; Büttner R; Perner S; Peifer M; Reinhardt HC
    Cancer Res; 2017 Jun; 77(11):3040-3056. PubMed ID: 28363999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer.
    Weber AM; Drobnitzky N; Devery AM; Bokobza SM; Adams RA; Maughan TS; Ryan AJ
    Oncotarget; 2016 Sep; 7(38):60807-60822. PubMed ID: 27602502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
    Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.
    Teng PN; Bateman NW; Darcy KM; Hamilton CA; Maxwell GL; Bakkenist CJ; Conrads TP
    Gynecol Oncol; 2015 Mar; 136(3):554-61. PubMed ID: 25560806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of tumour-specific ATM protein expression is an independent prognostic factor in early resected NSCLC.
    Petersen LF; Klimowicz AC; Otsuka S; Elegbede AA; Petrillo SK; Williamson T; Williamson CT; Konno M; Lees-Miller SP; Hao D; Morris D; Magliocco AM; Bebb DG
    Oncotarget; 2017 Jun; 8(24):38326-38336. PubMed ID: 28418844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin-mediated radiosensitization of non-small cell lung cancer cells is stimulated by ATM inhibition.
    Toulany M; Mihatsch J; Holler M; Chaachouay H; Rodemann HP
    Radiother Oncol; 2014 May; 111(2):228-36. PubMed ID: 24857596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
    Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
    PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
    Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
    Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of ATM in bystander signaling between human monocytes and lung adenocarcinoma cells.
    Ghosh S; Ghosh A; Krishna M
    Mutat Res Genet Toxicol Environ Mutagen; 2015 Dec; 794():39-45. PubMed ID: 26653982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the ataxia telangiectasia mutated gene in lung cancer: recent advances in research.
    Xu Y; Gao P; Lv X; Zhang L; Zhang J
    Ther Adv Respir Dis; 2017 Sep; 11(9):375-380. PubMed ID: 28825373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic and germline ATM variants in non-small-cell lung cancer: Therapeutic implications.
    Hernandez-Martinez JM; Rosell R; Arrieta O
    Crit Rev Oncol Hematol; 2023 Aug; 188():104058. PubMed ID: 37343657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers.
    Savva C; De Souza K; Ali R; Rakha EA; Green AR; Madhusudan S
    Breast Cancer Res Treat; 2019 May; 175(1):105-115. PubMed ID: 30746633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ataxia-telangiectasia-mutated protein expression with microsatellite instability in gastric cancer as prognostic marker.
    Kim JW; Im SA; Kim MA; Cho HJ; Lee DW; Lee KH; Kim TY; Han SW; Oh DY; Lee HJ; Kim TY; Yang HK; Kim WH; Bang YJ
    Int J Cancer; 2014 Jan; 134(1):72-80. PubMed ID: 23649938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of switch from ATM to ATR signaling at the sites of DNA damage induced by low and high LET radiation.
    Saha J; Wang M; Cucinotta FA
    DNA Repair (Amst); 2013 Dec; 12(12):1143-51. PubMed ID: 24238855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.